BOULDER, Colo., Oct. 31, 2022 (GLOBE NEWSWIRE) — SomaLogic (NASDAQ: SLGC), a pacesetter in AI data-driven proteomics know-how, as we speak introduced outcomes from key research demonstrating the broad function and depth that proteomics performs in detecting heart problems danger, attaining optimum cardiometabolic well being, and assessing the correlation of heart problems with different ailments which are among the many main causes of demise worldwide. SomaLogic and its analysis companions will current these research on the American Coronary heart Affiliation Scientific Classes in Chicago November 5-7, 2022.
“Proteomics is main the dialog on the AHA this 12 months with greater than 43 periods on the subject. SomaLogic is proud to be on the forefront of those discussions by main 5 oral and poster periods that present the worth of proteomics for the way forward for coronary heart and total well being,” stated Stephen Williams, MD, Ph.D., Medical Director of SomaLogic. “Think about a future the place a healthcare supplier is armed with perception into the prospects of affected person’s present and future well being, all from a single blood pattern.That future can change into a actuality once we mix proteomics testing with present care plans in a medical setting.
SomaLogic invitations AHA attendees to the next periods:
- Oral Session: Stroke Council Award – Greatest Scientific Analysis in Stroke
- Abstract: Proteomic indicators of cardiovascular well being linked to mind quantity and dementia danger
- When: Monday, November 7, 8:36-8:46 CT
- Location: N230B
- Submission #: 396
- Oral session: Understanding and modifying cardiovascular danger in diabetes
- Abstract: Protein Signatures of Cardiometabolic Ailments and GLP-1 Receptor Agonist Response within the EXSCEL Scientific Trial
- When: Monday, November 7, 1:30-1:35 p.m. CT
- Location: Zone 3‚ Science and Expertise Room‚ Stage 3
- Presentation #: 610
- Poster session: Uncovering the complicated relationship between adipokines, biomarkers and cardiometabolic well being
- Abstract: Weight reduction improves cardiometabolic well being as measured by plasma protein in folks with sort 2 diabetes
- When: Saturday, November 5, 11:00-12:00 CT
- Location: Zone 3, Science and Expertise Room, Stage 3
- Presentation #: SA3001
- Poster session: Observations on medical outcomes from the entrance traces of the COVID-19 pandemic
- Summary: Utility of a proteomic surrogate for cardiovascular outcomes to foretell and monitor COVID-19-induced myocarditis
- When: Sunday, November 6, 3:45-4:45 p.m. CT
- Location: Zone 2, Corridor of Science and Expertise, Stage 3
- Submission #: SU2115
- Poster Session: Biomarkers in Coronary heart Failure – Prognostic Indicators and Mechanistic Analysis
- Summary: Coronary heart failure subphenotypes with diminished ejection fraction primarily based on repeated measurements of 4210 circulating proteins are decided by protein subsets reflecting totally different organic mechanisms
- When: Sunday, November 6, 3:45-4:45 p.m. CT
- Location: Zone 2, Corridor of Science and Expertise, Stage 3
- Submission #: SU2184
“All of our research highlighted at AHA — in collaboration with our analysis companions — present the breadth and depth of our proteomics testing and testing, which excels at offering a holistic view of affected person well being whereas exploring the hyperlinks between heart problems and several other different therapeutic areas, together with dementia, sort 2 diabetes, COVID-19 and extra,” stated Dr. Williams.
Along with the presentation periods, SomaLogic may have a sales space within the exhibition corridor. AHA attendees can cease by sales space #2114 to attach with SomaLogic presenters, researchers and scientists. Life Science Corporations Can Talk about SomaLogic’s SomaScan® Analytical know-how and its functions for coronary heart illness analysis. Healthcare professionals can focus on SomaLogic’s SomaSignal™ check know-how and functions for SomaLogic’s CVD check that may assist physicians present precision affected person care.
About SomaLogic
SomaLogic (Nasdaq: SLGC) seeks to offer correct, significant, and actionable well being administration insights that allow people all over the world to constantly optimize their private well being and well-being all through their lives. This important info, to be offered by a world community of companions and customers, is derived from SomaLogic’s customized measurement of serious modifications in a person’s proteins over time. For extra info, go towww.somalogic.com and observe @somalogicon Twitter.
Disclaimer of Ahead-Wanting Statements
This press launch incorporates sure forward-looking statements throughout the which means of the “secure harbor” provisions of the Personal Securities Litigation Reform Act of 1995 and different federal securities legal guidelines. All statements, apart from statements of historic information included on this press launch, relating to our technique, future operations, monetary situation, estimated earnings, projections, outlook, plans and administration goals are statements potential. These forward-looking statements are usually recognized by the phrases “consider”, “undertaking”, “anticipate”, “steering”, “anticipate”, “anticipate”, “estimate”, “intend”, “technique “, “future”, “alternative”, “plan”, “could”, “ought to”, “will”, “would”, “will”, “proceed”, “most likely end result”, “potential”, “potential”, “predicts”, “pursues”, “targets” and comparable expressions, though not all forward-looking statements include such figuring out phrases. Ahead-looking statements are predictions, projections and different statements about future occasions which are primarily based on present expectations and assumptions and, due to this fact, are topic to dangers and uncertainties. Ahead-looking statements are usually not ensures of future efficiency and contain recognized and unknown dangers, uncertainties and different components. Many components may trigger precise future occasions to vary materially from the forward-looking statements contained on this press launch, together with components past SomaLogic’s management. It is best to rigorously take into account these dangers and uncertainties, together with, however not restricted to, the components described in Half I, Merchandise 1A – “Danger Elements” in our Annual Report on Type 10-Okay and different paperwork we file with the Securities and Alternate Fee. . These filings determine and deal with vital dangers and uncertainties that might trigger precise occasions and outcomes to vary materially from these contained within the forward-looking statements. Ahead-looking statements converse solely as of the date they’re made. Readers are cautioned to not place undue reliance on any forward-looking statements, and SomaLogic undertakes no obligation and doesn’t intend to replace or revise any such forward-looking statements, whether or not on account of new info, future occasions or in any other case. Ought to a number of of those dangers or uncertainties materialize, or ought to any of the assumptions show incorrect, precise outcomes could differ materially from these projected in these forward-looking statements. The Firm doesn’t undertake or undertake to replace or revise any forward-looking statements, whether or not on account of new info, future occasions or in any other case, besides as could also be required beneath the relevant securities legal guidelines.
Media Contact
Emilie Costales
720-798-5054
[email protected]
Investor contacts
Marissa Bych
Gilmartin Group LLC
[email protected]
